Alfacell to finish enrollment for Onconase phase 3b trial early

By Angela McDaniels

Seattle, Jan. 30 - Alfacell Corp. said it expects to reach full enrollment of 316 patients for its international phase 3b trial evaluating Onconase (ranpirnase) for the treatment of inoperable malignant mesothelioma ahead of schedule.

The previously announced timeframe was the end of the first quarter of 2005.

In addition, as a result of the fast track designation granted to Onconase by the FDA, the company plans to pursue expedited regulatory review of its New Drug Application upon filing.

Alfacell is a biopharmaceutical company based in Bloomfield, N.J., that discovers, develops and commercializes therapeutics for cancer using its proprietary RNase technology platform.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.